Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ALDH2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ALDH2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ALDH2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ALDH2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ALDH2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ALDH2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ALDH2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ALDH2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ALDH2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ALDH2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00229009 | Cervix | CC | electron transport chain | 53/2311 | 175/18723 | 2.23e-10 | 3.43e-08 | 53 |
GO:00060919 | Cervix | CC | generation of precursor metabolites and energy | 105/2311 | 490/18723 | 7.40e-09 | 6.61e-07 | 105 |
GO:000609124 | Cervix | N_HPV | generation of precursor metabolites and energy | 40/534 | 490/18723 | 2.59e-09 | 7.88e-07 | 40 |
GO:002290024 | Cervix | N_HPV | electron transport chain | 21/534 | 175/18723 | 2.95e-08 | 3.63e-06 | 21 |
GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
GO:0022900 | Colorectum | AD | electron transport chain | 89/3918 | 175/18723 | 1.42e-18 | 8.91e-16 | 89 |
GO:0044282 | Colorectum | AD | small molecule catabolic process | 118/3918 | 376/18723 | 1.05e-06 | 3.55e-05 | 118 |
GO:0006066 | Colorectum | AD | alcohol metabolic process | 106/3918 | 353/18723 | 3.02e-05 | 5.57e-04 | 106 |
GO:0034310 | Colorectum | AD | primary alcohol catabolic process | 9/3918 | 15/18723 | 1.11e-03 | 1.01e-02 | 9 |
GO:0034308 | Colorectum | AD | primary alcohol metabolic process | 35/3918 | 102/18723 | 1.16e-03 | 1.05e-02 | 35 |
GO:0006067 | Colorectum | AD | ethanol metabolic process | 11/3918 | 21/18723 | 1.43e-03 | 1.22e-02 | 11 |
GO:0006068 | Colorectum | AD | ethanol catabolic process | 7/3918 | 12/18723 | 5.09e-03 | 3.38e-02 | 7 |
GO:0046164 | Colorectum | AD | alcohol catabolic process | 20/3918 | 55/18723 | 6.03e-03 | 3.78e-02 | 20 |
GO:00060911 | Colorectum | SER | generation of precursor metabolites and energy | 168/2897 | 490/18723 | 1.39e-25 | 1.70e-22 | 168 |
GO:00229001 | Colorectum | SER | electron transport chain | 77/2897 | 175/18723 | 1.77e-19 | 1.36e-16 | 77 |
GO:00442821 | Colorectum | SER | small molecule catabolic process | 87/2897 | 376/18723 | 5.31e-05 | 1.27e-03 | 87 |
GO:00060661 | Colorectum | SER | alcohol metabolic process | 79/2897 | 353/18723 | 3.50e-04 | 5.50e-03 | 79 |
GO:00343101 | Colorectum | SER | primary alcohol catabolic process | 8/2897 | 15/18723 | 7.51e-04 | 9.68e-03 | 8 |
GO:00461641 | Colorectum | SER | alcohol catabolic process | 17/2897 | 55/18723 | 3.00e-03 | 2.65e-02 | 17 |
GO:00060681 | Colorectum | SER | ethanol catabolic process | 6/2897 | 12/18723 | 5.42e-03 | 4.03e-02 | 6 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0033023 | Oral cavity | LP | Arginine and proline metabolism | 26/2418 | 50/8465 | 3.94e-04 | 2.08e-03 | 1.34e-03 | 26 |
hsa0062022 | Oral cavity | LP | Pyruvate metabolism | 22/2418 | 47/8465 | 5.88e-03 | 2.31e-02 | 1.49e-02 | 22 |
hsa0028022 | Oral cavity | LP | Valine, leucine and isoleucine degradation | 22/2418 | 48/8465 | 7.98e-03 | 3.02e-02 | 1.95e-02 | 22 |
hsa0124021 | Oral cavity | LP | Biosynthesis of cofactors | 57/2418 | 153/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 57 |
hsa0001023 | Oral cavity | LP | Glycolysis / Gluconeogenesis | 28/2418 | 67/8465 | 1.36e-02 | 4.44e-02 | 2.86e-02 | 28 |
hsa0033033 | Oral cavity | LP | Arginine and proline metabolism | 26/2418 | 50/8465 | 3.94e-04 | 2.08e-03 | 1.34e-03 | 26 |
hsa0062032 | Oral cavity | LP | Pyruvate metabolism | 22/2418 | 47/8465 | 5.88e-03 | 2.31e-02 | 1.49e-02 | 22 |
hsa0028032 | Oral cavity | LP | Valine, leucine and isoleucine degradation | 22/2418 | 48/8465 | 7.98e-03 | 3.02e-02 | 1.95e-02 | 22 |
hsa0124031 | Oral cavity | LP | Biosynthesis of cofactors | 57/2418 | 153/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 57 |
hsa0001033 | Oral cavity | LP | Glycolysis / Gluconeogenesis | 28/2418 | 67/8465 | 1.36e-02 | 4.44e-02 | 2.86e-02 | 28 |
hsa003309 | Prostate | BPH | Arginine and proline metabolism | 18/1718 | 50/8465 | 7.17e-03 | 2.32e-02 | 1.43e-02 | 18 |
hsa0033012 | Prostate | BPH | Arginine and proline metabolism | 18/1718 | 50/8465 | 7.17e-03 | 2.32e-02 | 1.43e-02 | 18 |
hsa002807 | Prostate | Tumor | Valine, leucine and isoleucine degradation | 20/1791 | 48/8465 | 1.03e-03 | 4.59e-03 | 2.84e-03 | 20 |
hsa004104 | Prostate | Tumor | beta-Alanine metabolism | 13/1791 | 31/8465 | 7.13e-03 | 2.34e-02 | 1.45e-02 | 13 |
hsa000719 | Prostate | Tumor | Fatty acid degradation | 16/1791 | 43/8465 | 1.15e-02 | 3.59e-02 | 2.23e-02 | 16 |
hsa0028012 | Prostate | Tumor | Valine, leucine and isoleucine degradation | 20/1791 | 48/8465 | 1.03e-03 | 4.59e-03 | 2.84e-03 | 20 |
hsa0041011 | Prostate | Tumor | beta-Alanine metabolism | 13/1791 | 31/8465 | 7.13e-03 | 2.34e-02 | 1.45e-02 | 13 |
hsa0007112 | Prostate | Tumor | Fatty acid degradation | 16/1791 | 43/8465 | 1.15e-02 | 3.59e-02 | 2.23e-02 | 16 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
217 | ALDH2 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | ANS-6637 | | |
217 | ALDH2 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | CHEMBL964 | DISULFIRAM | |
217 | ALDH2 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | DISULFIRAM | DISULFIRAM | |
217 | ALDH2 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | 178103501 | PRUNETIN | |
217 | ALDH2 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | acetaldehyde | ACETALDEHYDE | 31002879 |
217 | ALDH2 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | heroin | DIACETYLMORPHINE | 21723677 |
217 | ALDH2 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | ALD-401 | | |
217 | ALDH2 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | DISULFIRAM | DISULFIRAM | |
217 | ALDH2 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | FP-045 | | |
217 | ALDH2 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | ETHANOL | ALCOHOL | 8986223 |